Results 201 to 210 of about 451,364 (309)

Performance of Novel Inflammatory Bowel Disease-Specific Models for Risk Adjustment. [PDF]

Risk Manag Healthc Policy
Moran KM, Hellems SS, Munshi KD, Smith I, Null KD.   +4 more
europepmc   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Editorial: Reviews in: multiple sclerosis and neuroimmunology. [PDF]

Front Neurol
Mirmosayyeb O.
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

LP-072 Validity of a claim-based algorithm for SLE disease severity to clinical SLE disease activity index in Korean patients with SLE

Lupus Science and Medicine, 2023
Sun-Young Jung, Yoon-Kyoung Sung, Soo-Kyung Cho, Eun Jin Jang, Hyoungyoung Kim, Eunwoo Nam   +5 more
doaj   +1 more source

INSIGHTS Asthma Pragmatic Registry - A Pragmatic Approach to High-Validity Real-World Evidence for Asthma. [PDF]

Pragmat Obs Res
Kilpatrick K, Chandran U, Urman R, Llanos JP, Molfino NA, Matsuno RK, Riskin DJ.   +6 more
europepmc   +1 more source

Commentary: Three questions for the study of traumatic brain injury in animals

The Anatomical Record, EarlyView.
Gregory Hollin
wiley   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Editorial: Exploring lymphatic vasculature's role in cardiovascular and metabolic diseases. [PDF]

Front Cardiovasc Med
Liu X, Yang X, Autieri MV.
europepmc   +1 more source

Risk of injury associated with the sedative potential of second‐generation antihistamines: A nationwide retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Individual second‐generation antihistamines may possess differential sedative potential due to the variability in central histamine receptor H1 occupancy. This study aimed to evaluate whether the sedative potential of second‐generation antihistamines is associated with the risk of injury during Japan's pollen season. Methods We conducted a
Jumpei Taniguchi, Shotaro Aso, So Sato, Hideo Yasunaga   +3 more
wiley   +1 more source